Adhesion G-protein coupled receptor G1 (ADGRG1)Links to databasesUniprot Q9Y653Receptor involved in cell adhesion and probably in cell-cell interactions. Mediates cell matrix adhesion in developing neurons and hematopoietic stem cells. Receptor for collagen III/COL3A1 in the developing brain and involved in regulation of cortical development, specifically in maintenance of the pial basement membrane integrity and in cortical lamination (By similarity). Binding to the COL3A1 ligand inhibits neuronal migration and activates the RhoA pathway by coupling to GNA13 and possibly GNA12 (PubMed:22238662). Plays a role in the maintenance of hematopoietic stem cells and/or leukemia stem cells in bone marrow niche (By similarity). Plays a critical role in cancer progression by inhibiting VEGFA production threreby inhibiting angiogenesis through a signaling pathway mediated by PRKCA (PubMed:16757564, PubMed:21724588). Plays an essential role in testis development (By similarity). ADGRG1 N-terminal fragment: Plays a critical role in cancer progression by activating VEGFA production and angiogenesis through a signaling pathway mediated by PRKCA (PubMed:21724588).Sample typeRecommended sample types are EDTA plasma and serum. A range of additional sample types are compatible with the technology (PEA), including citrate plasma, heparin plasma, cerebrospinal fluid, (CSF), tissue and cell lysates, fine needle biopsis, microdialysis fluid, cell culture media, dried blood spots, synovial fluid, saliva, plaque extract and microvesicles. Please note that protein expression levels are expected to vary in different sample types. Certain assays are differentially affected by interfering substances such as hemolysate. Download any of our Data Validation documents or contact support@olink.com for more information. Analytical Measuring RangePlease note: the technical data reported below refers to the measured value in the in vitro validation assays. The calibrator curve below shows the performance of the assay with the estimated sensitivity and dynamic range parameters indicated. These curves are generated during the assay validation process using recombinant antigens. Please note that when analyzing biological samples the data generated will be given in the form of relative quantification (NPX values) and cannot be converted to absolute protein concentrations. For more info about NPX measurements, please visit our FAQ page (https://www.olink.com/question/what-is-npx).LOD (pg/mL) 1953.12LLOQ (pg/mL) 1953.12ULOQ (pg/mL) 500000Hook (pg/mL)1000000Range (logs) 2.4Calibrator curve generated in multiplexPrecisionWithin run precision Coefficient of Variation (CV) 8%Between run precision Coefficient of Variation (CV)15%Precision (repeatability) is calculated from linearized NPX values over LOD.Biomarker Validation DataAdditional validation data, as well as a more detailed description of how the Olink panels are quality controlled can be found in our Data Validation documents. To download or to learn more go to the Data Validation page.View all Immuno-oncology panel biomarkers >View all biomarkers >
Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Our groundbreaking Olink panels for precision proteomics help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our high quality multiplex immunoassay panels help bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology.
Based on the pioneering research of Professor Ulf Landegren and his group at Uppsala University, Sweden, Olink was founded in 2004, The company has a successful history of developing molecular technologies, with a broad IP portfolio. Many of these have been commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink sold its highly successful Duolink product line for in situ detection of proteins to Sigma-Aldrich in 2015.
Following a company reorganization in April, 2016, Olink Proteomics is focusing entirely on developing and expanding its platform of high-multiplex immunoassay panels for protein biomarker discovery, while Olink Bioscience is responsible for the development and commercialization of the remaining extensive and expanding, diverse Olink IP portfolio. (You can read the press release here).
